TOKYO, Mar 24 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) reported completing several key milestones for its drug candidate OBP-301, including manufacturing and sales approval, price listing, and supply chain completion.
Additionally, the company achieved 24-month stability test clearance for Telemerysin in February 2026. Plans for further development include expanding efficacy trials and establishing new sales partnerships. Looking ahead, Oncolys aims to initiate clinical trials for OBP-601 and OBP-702, with T Co.
Planning to begin milestone payments and additional Alzheimer's disease trials. Okazaki University plans to commence the first clinical trial for OBP-702. The company also continues efforts to ensure stable product supply, having successfully produced clear products and confirmed 18-month stability, with future goals focusing on extending shelf life through 24-month and 36-month stability tests and maintaining inventory levels to prevent stockouts.
🟢 Confidence: High AI-translated content.